Search results for: 'sale to answer'

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

Laboratory personnel were invited to participate in an online survey in June 2014. A total of 366 laboratory decision makers qualified to complete the survey, answering questions about their use of laboratory information management systems (LIMS). Respondents organization types include academic laboratory or core facility; federal, state, or local...

Scope of the report The research report includes the following segments: Product scope: Pharmaceutical Products Geographic scope: Ethiopia End-user scope: Pharmaceutical manufacturers, Pharmaceutical distributors, Healthcare providers, Contract Manufacturing Organisations (CMO) Revenue analysis and forecasts, drivers and restraints, business opp...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...

The study covers current and future market trends, drivers, challenges, and opportunities in US therapeutic apheresis market. It breaks down the market into hematology and oncology, neurology, rheumatology, and other therapeutic areas. Therapeutic apheresis has become an essential element of the blood and blood components industry value chain. Hosp...

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

20 Jun 2017  |  North America  |  Market Research

Transformation and Growth Opportunities in the US Next-Generation Sequencing Informatics Market

Pharmaceutical and Molecular Diagnostics Segments to Lead Revenue Growth

Infographics

×

Frost & Sullivan expects strong demand for commercial application-focused solutions to drive new investments in the development of tools and technologies, and will also result in consolidation of the US next-generation sequencing informatics market. Changing customer requirements and intense competition will drive the transformation. As companies l...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2018 that centered around the state of their laboratories in 2018 and their expectations for 2019. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-o...